Valiant Organics Approves Q4 FY26 Results, Reappoints Cost & Internal Auditors
Valiant Organics Limited approved its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company identified Pharma Business as a new reportable segment. Smt. Ketki D. Visariya was reappointed as Cost Auditor and M/s. Manish Modi & Associates as Internal Auditor for FY 2026-27.
The approval of financial results and re-appointment of auditors are standard corporate governance procedures. The identification of a new business segment is a strategic development that could have a medium-term impact on the company's reporting and potentially its business focus.
The company reported improved financial results for the year ended March 31, 2026, with a significant increase in net profit compared to the previous year. The re-appointment of auditors and the identification of a new business segment are routine but positive corporate actions.
Valiant Organics Limited announced the outcome of its Board Meeting held on Saturday, May 16, 2026. The Board approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. The company also noted and approved the identification of Pharma Business as an additional reportable segment, alongside Specialty Chemicals.
Additionally, the Board approved the re-appointment of Smt. Ketki D. Visariya as the Cost Auditor and M/s. Manish Modi & Associates as the Internal Auditor for the financial year 2026-27. The Board meeting commenced at 12:50 P.M. (IST) and concluded at 2:45 P.M. (IST).
The financial results indicate a significant improvement in net profit for the year ended March 31, 2026, standing at ₹3,435.56 lakhs on a standalone basis and ₹3,322.85 lakhs on a consolidated basis, compared to a loss in the previous year. Revenue from operations for the year stood at ₹73,838.31 lakhs (standalone) and ₹73,875.87 lakhs (consolidated). For the quarter ended March 31, 2026, net profit was ₹1,511.74 lakhs (standalone) and ₹1,571.92 lakhs (consolidated).
What to do with a filing like this
Valiant Organics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Organics Limited. Read the original for the full detail.